Drug Profile
Grapiprant - AskAt
Alternative Names: 423; AAT-007; ARY 007; CJ-023; CJ-023,423; CJ-23423; IK 007; MR-10A7; RMX-1002; RQ-00000007; RQ-07; RQ-7Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer AskAt; HaiHe Biopharma; Ikena Oncology; M. D. Anderson Cancer Center; Ningbo NewBay Medical Technology; Pfizer
- Class Analgesics; Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Benzene derivatives; Imidazoles; Pyridines; Small molecules; Sulfonamides; Sulfonylureas
- Mechanism of Action Prostaglandin E EP4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Cancer pain; Neuropathic pain
- Phase II Pain
- Phase I/II Breast cancer; Non-small cell lung cancer
- Phase I Solid tumours
- Discontinued Colorectal cancer; Hypersensitivity; Inflammation
Most Recent Events
- 11 Sep 2023 Grapiprant is still in phase I trial for Solid tumours (Late-stage disease) in China (PO, Tablet) (RaQualia Pharma pipeline, September 2023)
- 07 Mar 2023 Arrys Therapeutics and Merck Sharp & Dohme completes a phase Ib trial in Colorectal cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) (NCT03658772)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)